Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)

Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

Am­gen said that an in­ter­im look at a Phase 2 tri­al of its an­ti-obe­si­ty drug Mar­i­Tide had left the com­pa­ny “very en­cour­aged,” and it planned …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.